10-K Filing

BEONE MEDICINES LTD. CIK: 1651308 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001651308-21-000039`
Period End Date	20201231
Filing Date	20210225
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	bgne-20201231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 95 Income Statement 94 Cash Flow Statement 160 Stockholders Equity 51 Comprehensive Income 29

Balance Sheet 95 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$712.94M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.54M	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.19B	shares	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	801.34M	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$307.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$364.73M	USD	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$3.27B	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$60.40M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$70.88M	USD	Point-in-time
Inventories	`InventoryNet`	$89.29M	USD	Point-in-time
Inventories	`InventoryNet`	$28.55M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$160.01M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$90.24M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.96B	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$7.75M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$13.23M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$357.69M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$242.40M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$90.58M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$82.52M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.00M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.85M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$65.96M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$37.89M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$113.09M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$68.45M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$640.07M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$439.59M	USD	Point-in-time
Total assets	`Assets`	$5.60B	USD	Point-in-time
Total assets	`Assets`	$1.61B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$122.49M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$231.96M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$346.14M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$163.56M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$13.45M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$20.38M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$10.81M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$13.89M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	-	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$127.81M	USD	Point-in-time
Short-term debt	`ShortTermBorrowings`	-	USD	Point-in-time
Short-term debt	`ShortTermBorrowings`	$335.01M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$310.31M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.08B	USD	Point-in-time
Long-term bank loans	`LongTermDebtNoncurrent`	580.00M	CNY	Point-in-time
Long-term bank loans	`LongTermDebtNoncurrent`	$83.31M	USD	Point-in-time
Long-term bank loans	`LongTermDebtNoncurrent`	1.20B	CNY	Point-in-time
Long-term bank loans	`LongTermDebtNoncurrent`	$183.64M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	0.00	CNY	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$157.38M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	-	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	900.00M	CNY	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$29.42M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$25.83M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.79M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.53M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$375.04M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	-	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$57.43M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$46.56M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$656.32M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$323.62M	USD	Point-in-time
Total liabilities	`Liabilities`	$633.93M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.73B	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,190,821,941 and 801,340,698 shares issued and outstanding as of December 31, 2020 and 2019, respectively	`CommonStockValue`	$79.00K	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,190,821,941 and 801,340,698 shares issued and outstanding as of December 31, 2020 and 2019, respectively	`CommonStockValue`	$118.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$7.41B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$2.93B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$6.94M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-8.00M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.96B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.55B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$962.21M	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$3.87B	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$16.15M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	-	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$684.23M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.87B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$1.61B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$5.60B	USD	Point-in-time

Income Statement 94 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$52.06M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$77.83M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$243.35M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$308.87M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$100.10M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$198.22M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$428.21M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$50.14M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$65.64M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$56.89M	USD	1 Quarter
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$91.08M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$70.66M	USD	Annual
Cost of sales - product	`CostOfGoodsAndServicesSold`	$71.19M	USD	Annual
Cost of sales - product	`CostOfGoodsAndServicesSold`	$28.70M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.29B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$679.00M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$927.34M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$388.25M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$195.38M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$600.18M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.33M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$846.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$894.00K	USD	Annual
Total expenses	`CostsAndExpenses`	$1.39B	USD	Annual
Total expenses	`CostsAndExpenses`	$903.99M	USD	Annual
Total expenses	`CostsAndExpenses`	$1.97B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-358.88M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-373.76M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-440.14M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-173.75M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-312.27M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-705.77M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.66B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-959.89M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-484.91M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-85.83M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-388.04M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$9.13M	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$2.00M	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$13.95M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$7.17M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$37.49M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$1.99M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.62B	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-689.83M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-943.59M	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$6.99M	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-17.67M	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-15.80M	USD	Annual
Net loss	`ProfitLoss`	$-674.03M	USD	Annual
Net loss	`ProfitLoss`	$-387.89M	USD	1 Quarter
Net loss	`ProfitLoss`	$-472.65M	USD	1 Quarter
Net loss	`ProfitLoss`	$-426.62M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-308.66M	USD	1 Quarter
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-3.62M	USD	Annual
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.95M	USD	Annual
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-264.00K	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-335.20M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-167.64M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-673.77M	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-948.63M	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-388.06M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-307.36M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-425.22M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-85.57M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-363.74M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-1.60B	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-472.75M	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-1.47	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-1.22	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.36	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.93	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.49	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.11	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.37	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.40	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.39	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.33	USD	1 Quarter
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	720.75M	shares	Annual
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	780.70M	shares	Annual
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.09B	shares	Annual
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-19.13	USD	Annual
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-12.15	USD	Annual
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-15.80	USD	Annual
Weighted-average ADSs outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	83.47M	shares	Annual
Weighted-average ADSs outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	60.05M	shares	Annual
Weighted-average ADSs outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	55.44M	shares	Annual

Cash Flow Statement 160 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-674.03M	USD	Annual
Net loss	`ProfitLoss`	$-387.89M	USD	1 Quarter
Net loss	`ProfitLoss`	$-472.65M	USD	1 Quarter
Net loss	`ProfitLoss`	$-426.62M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-308.66M	USD	1 Quarter
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$18.62M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$10.39M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$31.79M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$87.13M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$183.48M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$134.15M	USD	Annual
Research and Development in Process	`ResearchAndDevelopmentInProcess`	$69.00M	USD	Annual
Research and Development in Process	`ResearchAndDevelopmentInProcess`	$70.00M	USD	Annual
Research and Development in Process	`ResearchAndDevelopmentInProcess`	$109.50M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-113.99M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Gains (losses) from equity investments	`IncomeLossFromEquityMethodInvestments`	$11.83M	USD	Annual
Gains (losses) from equity investments	`IncomeLossFromEquityMethodInvestments`	-	USD	Annual
Gains (losses) from equity investments	`IncomeLossFromEquityMethodInvestments`	-	USD	Annual
Gain on deconsolidation of a subsidiary	`DeconsolidationGainOrLossAmount`	$11.31M	USD	Annual
Gain on deconsolidation of a subsidiary	`DeconsolidationGainOrLossAmount`	-	USD	Annual
Gain on deconsolidation of a subsidiary	`DeconsolidationGainOrLossAmount`	-	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-21.95M	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-9.23M	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-27.81M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$6.63M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-1.40M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-2.04M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$11.63M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$29.82M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-10.36M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$58.91M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$12.31M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$5.31M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$38.61M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$65.53M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-45.00K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$20.78M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$40.23M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-9.31M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$23.47M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.22M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$95.83M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$64.03M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$50.54M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$182.69M	USD	Annual
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$7.57M	USD	Annual
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-3.35M	USD	Annual
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$2.32M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-9.06M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-27.98M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-2.28M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	-	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-102.00K	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$16.96M	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$-25.40M	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$8.48M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-750.27M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.28B	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-547.72M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$70.28M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$89.61M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$117.51M	USD	Annual
Deconsolidation of a subsidiary	`CashDivestedFromDeconsolidation`	-	USD	Annual
Deconsolidation of a subsidiary	`CashDivestedFromDeconsolidation`	$2.02M	USD	Annual
Deconsolidation of a subsidiary	`CashDivestedFromDeconsolidation`	-	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$553.00K	USD	Annual
Payment for asset acquisition, net of cash acquired	`PaymentForAssetAcquisition`	-	USD	Annual
Payment for asset acquisition, net of cash acquired	`PaymentForAssetAcquisition`	-	USD	Annual
Payment for asset acquisition, net of cash acquired	`PaymentForAssetAcquisition`	$38.30M	USD	Annual
Payments to Acquire Investments	`PaymentsToAcquireInvestments`	$1.17B	USD	Annual
Payments to Acquire Investments	`PaymentsToAcquireInvestments`	$5.69B	USD	Annual
Payments to Acquire Investments	`PaymentsToAcquireInvestments`	$2.64B	USD	Annual
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$2.75B	USD	Annual
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$1.88B	USD	Annual
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$2.18B	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$69.00M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$109.50M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$70.00M	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.17B	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-637.61M	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$554.16M	USD	Annual
Proceeds from Issuance Initial Public Offering	`ProceedsFromIssuanceInitialPublicOffering`	$757.59M	USD	Annual
Proceeds from Issuance Initial Public Offering	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from Issuance Initial Public Offering	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from public offering and HK IPO, net	`ProceedsFromCommonStockIssuanceAndInitialPublicOffering`	$869.71M	USD	Annual
Proceeds from public offering and HK IPO, net	`ProceedsFromCommonStockIssuanceAndInitialPublicOffering`	-	USD	Annual
Proceeds from public offering and HK IPO, net	`ProceedsFromCommonStockIssuanceAndInitialPublicOffering`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	$4.23B	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	$616.83M	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Payment to acquire joint venture ("JV") minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	-	USD	Annual
Payment to acquire joint venture ("JV") minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	$28.72M	USD	Annual
Payment to acquire joint venture ("JV") minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	-	USD	Annual
Proceeds from loans	`ProceedsFromIssuanceOfDebt`	$67.49M	USD	Annual
Proceeds from loans	`ProceedsFromIssuanceOfDebt`	$42.31M	USD	Annual
Proceeds from loans	`ProceedsFromIssuanceOfDebt`	$433.90M	USD	Annual
Repayment of loans	`RepaymentsOfDebt`	$144.31M	USD	Annual
Repayment of loans	`RepaymentsOfDebt`	$8.74M	USD	Annual
Repayment of loans	`RepaymentsOfDebt`	$32.81M	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	$4.00M	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	-	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	-	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$29.66M	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$47.00M	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$93.10M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$85.68M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.20B	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.69B	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.23M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-9.51M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-4.10M	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-119.94M	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$501.11M	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$769.23M	USD	Annual
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.60M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$712.94M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.54M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$307.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$7.75M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$13.23M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$10.60M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$8.98M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$12.36M	USD	Annual
Interest paid	`InterestPaidNet`	$2.21M	USD	Annual
Interest paid	`InterestPaidNet`	$4.32M	USD	Annual
Interest paid	`InterestPaidNet`	$44.13M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$42.76M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$22.11M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$29.09M	USD	Annual
Purchase of in-process research and development included in accounts payable	`PurchaseofInprocessanddevelopmentIncludedinAccountsPayable`	$19.00M	USD	Annual
Purchase of in-process research and development included in accounts payable	`PurchaseofInprocessanddevelopmentIncludedinAccountsPayable`	-	USD	Annual
Purchase of in-process research and development included in accounts payable	`PurchaseofInprocessanddevelopmentIncludedinAccountsPayable`	-	USD	Annual
Changes in operating assets and liabilities adjusted through accumulated deficit	`AdjustmentstoChangesinOperatingAssetsandLiabilities`	-	USD	Annual
Changes in operating assets and liabilities adjusted through accumulated deficit	`AdjustmentstoChangesinOperatingAssetsandLiabilities`	$2.29M	USD	Annual
Changes in operating assets and liabilities adjusted through accumulated deficit	`AdjustmentstoChangesinOperatingAssetsandLiabilities`	-	USD	Annual

Stockholders Equity 51 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$684.23M	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.87B	USD	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time
Issuance of ordinary shares in connection	`StockIssuedDuringPeriodValueNewIssues`	$2.07B	USD	Annual
Contributions from shareholders	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$4.00M	USD	Annual
Use of shares reserved for share option exercises and RSU releases	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.00K	USD	Annual
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$134.15M	USD	Annual
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$183.48M	USD	Annual
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$87.13M	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$29.66M	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$47.00M	USD	Annual
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$93.10M	USD	Annual
Deconsolidation of a subsidiary	`NoncontrollingInterestDecreaseFromDeconsolidation`	$3.54M	USD	Annual
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	`MinorityInterestDecreaseFromRedemptions`	$28.71M	USD	Annual
Other comprehensive income/(loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-9.87M	USD	Annual
Other comprehensive income/(loss)	`OtherComprehensiveIncomeLossNetOfTax`	$15.07M	USD	Annual
Other comprehensive income/(loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.66M	USD	Annual
Net Income (Loss) Attributable to Noncontrolling Interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-3.62M	USD	Annual
Net Income (Loss) Attributable to Noncontrolling Interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.95M	USD	Annual
Net Income (Loss) Attributable to Noncontrolling Interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-264.00K	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-335.20M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-167.64M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-673.77M	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-948.63M	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-388.06M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-307.36M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-425.22M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-85.57M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-363.74M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-1.60B	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-472.75M	USD	1 Quarter
Net loss	`ProfitLoss`	$-674.03M	USD	Annual
Net loss	`ProfitLoss`	$-387.89M	USD	1 Quarter
Net loss	`ProfitLoss`	$-472.65M	USD	1 Quarter
Net loss	`ProfitLoss`	$-426.62M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-308.66M	USD	1 Quarter
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$684.23M	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.87B	USD	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time

Comprehensive Income 29 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-674.03M	USD	Annual
Net loss	`ProfitLoss`	$-387.89M	USD	1 Quarter
Net loss	`ProfitLoss`	$-472.65M	USD	1 Quarter
Net loss	`ProfitLoss`	$-426.62M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-308.66M	USD	1 Quarter
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-9.42M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-478.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$23.60M	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$8.11M	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	-	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	-	USD	Annual
Unrealized holding (loss) gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$2.13M	USD	Annual
Unrealized holding (loss) gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-419.00K	USD	Annual
Unrealized holding (loss) gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-448.00K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.59B	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-960.45M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-672.38M	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-352.00K	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-2.29M	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-3.49M	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-1.58B	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-672.03M	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-958.15M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.